Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06218082 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Vitiligo Registry for Adults and Children in the UK

Study acronym: VIRTUAL-UK
StatusNot Yet Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Start date: May 15, 2026 to Dec 15, 2026
    • Eligibility criteria expanded, about 8 words
    • Secondary endpoints: details revised at 1 of 8 entries
  2. Start date: Feb 15, 2026 to May 15, 2026
    • Primary completion pushed from Apr 2027 to May 2027
    • Study completion pushed from Dec 2029 to Feb 2030
    v11
  3. Start date: Dec 15, 2025 to Feb 15, 2026
    • Primary completion date: Dec 2027 to Apr 2027
    • Study completion date: Oct 2029 to Dec 2029
    v10
  4. Start date: Sep 15, 2025 to Dec 15, 2025
    • Primary completion date: Sep 2027 to Dec 2027
    • Study completion date: Jul 2029 to Oct 2029
    v9
  5. Start date: Jul 15, 2025 to Sep 15, 2025
    • Primary completion date: Jul 2027 to Sep 2027
    • Study completion date: May 2029 to Jul 2029
    v8
Show 6 earlier versionsHide 6 earlier versions
  1. Start date: May 15, 2025 to Jul 15, 2025
    • Primary completion date: May 2027 to Jul 2027
    • Study completion date: Mar 2029 to May 2029
    v7
  2. Trial status: Recruiting to Not Yet Recruiting
    • Site details revised
    v6
  3. Primary completion date: Mar 2029 to May 2027
    • Start date: May 31, 2024 to May 15, 2025
    v5
  4. Trial status: Not Yet Recruiting to Recruiting
    • Start date: Apr 1, 2024 to May 31, 2024
    • Study sites: 0 to 1
    • Collaborators expanded, about 4 words
    v4
  5. Start date: Mar 1, 2024 to Apr 1, 2024
    • Primary completion date: Feb 2029 to Mar 2029
    • Study completion date: Feb 28, 2029 to Mar 2029
    v3
  6. Primary completion date: Jul 31, 2026 to Feb 2029
    • Study completion date: Jul 31, 2026 to Feb 28, 2029
    • Start date: Jul 31, 2024 to Mar 1, 2024
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Vitiligo is the most common depigmentation disorder affecting around 1% of the population worldwide. Fifty two percent of patients develop vitiligo before the age of 20 and around 80% develop vitiligo before the age of 30 years old.1 Vitiligo often presents in childhood and tends to be a lifelong disease, requiring prolonged courses of phototherapy. Currently no national or international registry for patients with vitiligo exists. Individual dermatologists maintain a database of such patients, however no coordinated efforts have been made to combine these individual registries into a broader national registry. Finally, recently published British Association of Dermatologists (BAD) guideline for the management of vitiligo, recommended the development of a national registry for people with vitiligo undergoing systemic or light therapy to identify outcomes and safety.
Trial Details
NCT Number NCT06218082
Lead Sponsor The Royal Wolverhampton Hospitals NHS Trust
Collaborators: Incyte Biosciences International Sàrl
Conditions
(from sponsor)		 Dermatologic Disease, Vitiligo
Related terms Skin Diseases, Vitiligo
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov